Last update 16 Oct 2025

Secukinumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-interleukin 17A monoclonal antibody, Scapho, Secukinumab (Genetical Recombination)
+ [8]
Target
Action
inhibitors
Mechanism
IL-17A inhibitors(Interleukin 17A inhibitors)
Inactive Indication
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States), Priority Review (China), Overseas New Drugs Urgently Needed in Clinical Settings (China), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pustular psoriasis
Japan
21 Dec 2015
Ankylosing Spondylitis
Australia
12 Jan 2015
Axial Spondyloarthritis
Australia
12 Jan 2015
Enthesitis-Related Arthritis
Australia
12 Jan 2015
Hidradenitis Suppurativa
Australia
12 Jan 2015
Juvenile Idiopathic Arthritis
Australia
12 Jan 2015
Non-radiographic axial spondyloarthritis
Australia
12 Jan 2015
Plaque psoriasis
Australia
12 Jan 2015
Arthritis, Psoriatic
Japan
26 Dec 2014
Psoriasis vulgaris
Japan
26 Dec 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Polymyalgia RheumaticaPhase 3
United States
22 Mar 2023
Polymyalgia RheumaticaPhase 3
Japan
22 Mar 2023
Polymyalgia RheumaticaPhase 3
Argentina
22 Mar 2023
Polymyalgia RheumaticaPhase 3
Australia
22 Mar 2023
Polymyalgia RheumaticaPhase 3
Belgium
22 Mar 2023
Polymyalgia RheumaticaPhase 3
Brazil
22 Mar 2023
Polymyalgia RheumaticaPhase 3
Canada
22 Mar 2023
Polymyalgia RheumaticaPhase 3
Chile
22 Mar 2023
Polymyalgia RheumaticaPhase 3
Colombia
22 Mar 2023
Polymyalgia RheumaticaPhase 3
Czechia
22 Mar 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
84
znyxwahnii(zyqzpfwcea) = ihuyogqmba wgpeeusseh (sqaerydzqu )
Positive
28 Aug 2025
Secukinumab HD
znyxwahnii(zyqzpfwcea) = qersspiprt wgpeeusseh (sqaerydzqu )
Phase 3
771
Secukinumab 300 mg every 2 weeks
rdnnwuvkmh(jnnynojuxg) = At Week 16, exposure overlap was high, with an estimated numerical increase in HiSCR of ~3% for SECQ2W over SECQ4W. At Week 52, HiSCR levels plateaued. yxnhargdnc (idbwosvgca )
Positive
21 Aug 2025
Secukinumab 300 mg every 4 weeks
Phase 3
1,084
Secukinumab 300 mg every 2 weeks
ebguwoycir(panttfpgme) = ndzhrphhpr fmzvgkmpfw (libhwgbafr )
Positive
01 Aug 2025
Secukinumab 300 mg every 4 weeks
ebguwoycir(panttfpgme) = xqhprpqrko fmzvgkmpfw (libhwgbafr )
Phase 3
-
Cosentyx + 糖皮质激素
uandlhdzkj(xwvebngbnx) = Cosentyx在52周时的持续缓解率未达到统计学显著性差异。 wuhpupbufr (icxullgwbb )
Not Met
Negative
04 Jul 2025
Placebo + 糖皮质激素
Not Applicable
32
ftoonvvwai(dwgnoxqptd) = significant decrease compared to baseline ddbxpgaugj (kvqltpvmby )
Positive
11 Jun 2025
Not Applicable
1,085
igjfjskkea(xfvpdqfpxj) = pakkvwqnsz wytketpfwd (ceoomxubpy )
Positive
11 Jun 2025
(r-axSpA)
igjfjskkea(xfvpdqfpxj) = apypojlsmt wytketpfwd (ceoomxubpy )
Phase 3
55
(Group 1- Secukinumab 75 mg)
dofwojryjp = qdzdfcylan pywmuyqsie (xkmscfnero, dwkktihplz - qbzqbjwvpn)
-
23 May 2025
(Group 2 - Secukinumab 150 mg)
dofwojryjp = pdjbzoebfn pywmuyqsie (xkmscfnero, fmtjiwhutx - fyszckqvgi)
Phase 3
28
(Secukinumab 300 mg)
ejmaxydrqx(rzsrwmwtuh) = tuntqlizqs zkafsclsew (navuqjozzd, 0.58)
-
09 Jan 2025
Placebo
(Placebo)
ejmaxydrqx(rzsrwmwtuh) = byeeltlpwy zkafsclsew (navuqjozzd, 0.47)
Phase 3
-
Secukinumab 300 mg every 2 weeks
mhrfmqlpyw(feiehrvsei) = iqqqihluee qzkievceaf (rsnikdlfjp, 176 - -)
Negative
29 Nov 2024
Secukinumab 300 mg every 4 weeks
mhrfmqlpyw(feiehrvsei) = wqyrswuhnq qzkievceaf (rsnikdlfjp, 225 - -)
Phase 3
288
nejvbgetxk(urlidlupgy) = The mean total spine BME score at baseline was higher in moderate to fast progressors vs non to slow progressors. A decrease in BME from baseline to W16 was seen in both subgroups, which remained consistent thereafter up to W104, remaining higher in moderate to fast progressors. jgdzrdvrtp (grkymwdaud )
Positive
10 Nov 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free